EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study

Ting Deng, Feixue Wang, Le Zhang, Tao Ning, Yansha Sun, Shaohua Ge, Ming Bai, Yao Lu, Hongli Li, Yi Ba

Cancer Immunology, Immunotherapy · 04.06.2024 · 73 (8)

DOI: 10.1007/s00262-024-03743-0 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 04.06.2024. Verfasst von Ting Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's …. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Antineoplastic Combined Chemotherapy Protocols, Stomach Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Tianjin Key Medical Discipline (Specialty) Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alpha-fetoprotein elevated gastric cancer (AFPGC) got growing interests for its aggressive nature and unfavorable prognosis. Here, a phase 1 dose escalation study was conducted to evaluate safety and efficacy of zimberelimab (GLS-010, anti-PD-1) plus lenvatinib and chemotherapy (XELOX) as the first-line treatment for AFPGC.

Methods

Histologically confirmed HER2-negative, advanced GC patients with elevated serum AFP level (≥ 20 ng/ml) were screened. Using a 3 + 3 dose escalation design, patients were administered varying doses of lenvatinib (12, 16, 20 mg) with GLS-010 and XELOX. The primary endpoints were safety and determination of recommended phase II dose (RP2D). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS) and disease control rate.

Results

Nine patients were enrolled with no dose-limiting toxicities observed. Most frequent treatment-related AEs were fatigue (55.6%), hand-foot syndrome (55.6%) and rash (55.6%), and no grade ≥ 4 AEs were reported. All patients exhibited disease control with ORR reaching 33.3%. The median PFS and OS reached 7.67 months (95% CI 4.07–11.27) and 13.17 months (95% CI 2.78–23.56), respectively. Serum AFP level was found correlated with therapeutic responses. Further 16s rRNA sequencing analysis demonstrated altered gut microbiota with elevated abundance of Lachnospiraceae bacterium-GAM79 and Roseburia hominis A2-183.

Conclusions

GLS-010 plus lenvatinib and XELOX demonstrated a manageable safety profile with promising efficacy for AFPGC. With RP2D of lenvatinib determined as 16 mg, further expansion cohort is now ongoing. Translational investigation suggested that serum AFP can be indictive for therapeutic responses and certain microbiota species indicating favorable responses to immunotherapy was elevated after the combinational treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesPhenylurea CompoundsAntineoplastic Combined Chemotherapy ProtocolsStomach Neoplasmsalpha-FetoproteinsHumansMaleFemaleMiddle AgedAgedAntibodies, Monoclonal, HumanizedAdultPrognosis

Stichwörter der Autor:innen

AFPGastric cancerImmunotherapyPhase 1 trial

Substanzen

lenvatinibQuinolinesPhenylurea Compoundsalpha-FetoproteinsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digesti…
  • Department of Medical Oncology, Department of Cancer Center, Peking Union Medical College Hospital, Beijing, China. bayi@tjmuch.com.

Förderung

  • National Natural Science Foundation of China
  • Tianjin Key Medical Discipline (Specialty) Construction Project

Zitieren

APA

Deng, T., Wang, F., Zhang, L., Ning, T., Sun, Y., Ge, S., Bai, M., Lu, Y., Li, H., & Ba, Y. (2024). Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study. Cancer Immunology, Immunotherapy, 73(8). https://doi.org/10.1007/s00262-024-03743-0

Vancouver

Deng T, Wang F, Zhang L, Ning T, Sun Y, Ge S, et al. Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study. Cancer Immunology, Immunotherapy. 2024;73(8). doi:10.1007/s00262-024-03743-0

BibTeX
@article{Deng2024,
  author = {Deng, Ting and Wang, Feixue and Zhang, Le and Ning, Tao and Sun, Yansha and Ge, Shaohua and Bai, Ming and Lu, Yao and Li, Hongli and Ba, Yi},
  title = {Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {8},
  doi = {10.1007/s00262-024-03743-0}
}
Kostenlos starten →